Three things to know:
1. i-FACTOR is one of two drug-device combination products approved by the FDA through the premarket approval process. It’s supported by level 1 data.
2. The combination is designed to induce osteoblast cell proliferation and differentiation to accelerate new bone formation in degenerative disc disease patients.
3. Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide technology platform. i-FACTOR incorporates a small peptide as an attachment factor to stimulate the bone healing process.
Click here to see the ISASS bone grafting policy.
More articles on biologics:
Aesculap Biologics reaches halfway mark in clinical trial for knee articular cartilage defects: 5 insights
Global autologous matrix-induced chondrogenesis market to reach $186.4M by 2024 — 3 insights
Dr. Roger Hartl: The biggest opportunity in spinal biologics
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
